Imugene Limited, an Australian Biotech company specializing in biological animal health products, and Merial Limited announced the signing of three commercial contracts, which could lead to products for food producing animals based on a novel technology platform.

The contracts have been agreed between Merial and VectoGen, a production animal biotechnology company recently acquired by Imugene. Two of these contracts are evaluation and sublicense option agreements for products to treat of prevent diseases of poultry. The third contract is for the evaluation of the vector for the possible development of a vaccine for the prevention of viral diseases in pigs.

The contractors also provide for the evaluation of biologically based products including productivity enhancers and vaccines to prevent diseases. The products are residue-free and do not contribute to antibiotic resistance.